-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fosun Pharma's third-quarter 2018 report showed revenue of RMB18,142 million in the first three quarters, up 39.99% YoY, while net profit attributable to shareholders of listed companies was RMB2,094 million, down 13.44% YoY.
China Network financial reporter combed Fosun Pharma's recent results found that from 2014 to 2017, Fosun Pharma's annual revenue and net profit showed double growth, but the increase in net profit decreased year by year.
Fosun Pharma explained the decline in net profit in its third-quarter report, saying it was mainly affected by higher investment in innovative research and development and business layout, losses at some participating companies and higher interest expense. China Net Finance reporter called Fosun Pharma to inquire about the details, the phone could not be connected.
, founder of Beijing Dingchen Pharmaceuticals, said Fosun Pharma's net profit decline was caused by a variety of factors. "On the one hand, the policy environment will affect all pharmaceutical companies, and on the other hand, Fosun Pharma has been under greater financial pressure as a result of the acquisition, with too much external debt and too much receivables. At the same time, Fosun Pharma's sales rely too much on the distribution capacity of China National Pharmaceutical Holdings, the distribution capacity of China National Pharmaceuticals Holdings declined, Fosun Pharma was affected to some. (China Net Finance)
